Ana M. Gonzalez‐Angulo

Carla L. Warneke

Chad Barnett

Deemarsky L

Elizabeth A. Mittendorf

Gabriel N. Hortobágyi

George H. Perkins

Henry M. Kuerer

Jennifer K. Litton

Karin M. Hahn

Richard L. Theriault

Shana L. Palla

Abstract
               
                  Learning Objectives
                  Discuss known data regarding outcomes in pregnancy-associated breast cancer. Evaluate outcomes in a single institution when compared to nonpregnant breast cancer patients.
               
               
                  Background.
                  The purpose of this analysis was to compare disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) between pregnant and nonpregnant patients with breast cancer.
               
               
                  Methods.
                  From 1989 to 2009, 75 women were treated with chemotherapy during pregnancy. Each pregnant case was matched on age and cancer stage to two nonpregnant patients with breast cancer (controls). Fisher's exact test, the Kaplan-Meier method, and Cox proportional hazards regression models were used.
               
               
                  Results.
                  Median follow-up time for patients who were alive at the end of follow-up (n = 159) was 4.20 years (range: 0.28–19.94 years). DFS at 5 years was 72% (95% confidence interval [CI]: 58.3%–82.1%) for pregnant patients and 57% (95% CI: 46.7%–65.8%) for controls (p = .0115). Five-year PFS was 70% (95% CI: 56.8%–80.3%) for pregnant patients and 59% (95% CI: 49.1%–67.5%) for controls (p = .0252). Five-year OS was 77% (95% CI: 63.9%–86.4%) for pregnant patients and 71% (95% CI: 61.1%–78.3%) for controls (p = .0461). Hazard ratio estimates favored improved survival for pregnant patients in univariate analyses and multivariate analyses, controlling for age, year of diagnosis, stage, and tumor grade.
               
               
                  Conclusions.
                  For patients who received chemotherapy during pregnancy, survival was comparable to—if not better than—that of nonpregnant women. Pregnant patients with breast cancer should receive appropriate local and systemic therapy for breast cancer.
               </jats:sec

Ana M. Gonzalez-Angulo

Crossref

The Oncologist

Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer

Case Control Study of Women Treated With Chemotherapy for Breast Cancer During Pregnancy as Compared With Nonpregnant Patients With Breast Cancer

Abstract

Similar works

Full text

Available Versions

Crossref